e-GOLIAH in Autistic Spectrum Disorders (e-GOLIAH-ECO)

April 15, 2022 updated by: Assistance Publique - Hôpitaux de Paris

Medico-economic Evaluation of the Care by Serious Games in Outpatient Units and at Home for Children With Autism Spectrum Disorders

Randomized open-label study comparing children aged 3 to 6 years with autism and normal cognitive development or mild cognitive impairment receiving the usual treatment plus intensive use of eGOLIAH (experimental group) with children receiving only the usual treatment (control group).

eGOLIAH (Gaming Open Library for Intervention in Autism at Home) is an accessible online platform for digital games inspired by the principles of the Early Start Denver Model (ESDM), one of the care programs validated in the management of young ASD.

The duration per patient will be one year. The exposure to e-GOLIAH for the experimental group will be done with the recommendation of intensive exposure to the game (5 sessions> ½ hour per week).

Clinical variables will be assessed at entry, 6 months and 1 year (end of study).

The EQ5D questionnaires will be collected by the supervising therapist during the follow-up visit and at the same time as the clinical variables.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

In a context of increasing prevalence of Autism Spectrum Disorder (ASD) and the heterogeneity of children's profiles and abilities, early diagnosis is crucial in order to implement intensive, individualized, multidimensional therapeutic care and therefore more efficient. In the context of MICHELANGELO (FP7 European Research project), we developed a serious game called GOLIAH for Gaming Open Library for Intervention for Autism at Home. Using the first beta version as functional prototype, we showed that the demonstrator could be used at home with the help of parents in addition to usual care, during a clinical study including 25 participants. Also, Billeci and colleagues showed that, after training, children's improvement in joint attention tasks was correlated with changes in brain activity and connectivity. We then developed a new version e-GOLIAH to open the opportunity to conduct a large clinical study to assess the validity of the tool in terms of children's improvements. The goals of e-GOLIAH are to bring improvements in terms of ergonomics and accessibility to this initial prototype by finalizing the tool and distributing it to therapists, parents and children with ASD, via the Curapy.com web platform. e-GOLIAH provides, in free and open access, a platform for digital games inspired by the principles of ESDM (Early Start Denver Model) allowing intensive training to improve joint attention and imitation, two key skills for early social interaction and communication. It is a more natural, child-centered intervention method practiced at home and involving parents. This innovative solution takes the assessment and management of autism care out of the usual clinical environment. eGOLIAH (Gaming Open Library for Intervention in Autism at Home) is an accessible online platform for digital games that include ten different games with different level of complexity. A key principle is the collaboration between the child and his/her parent to proceed with the games making it interactive by nature, each participant having his own tablet.

The current study e-GOLIAH-ECO is a medico-economic study powered to recruit 150 children. It is a multisite randomized open-label study comparing children aged 3 to 6 years with autism and normal cognitive development or mild cognitive impairment receiving the usual treatment plus intensive use of eGOLIAH (experimental group) with children receiving only the usual treatment (control group).

The duration per patient will be one year. The exposure to e-GOLIAH for the experimental group will be done with the recommendation of intensive exposure to the game (5 sessions> ½ hour per week).

Clinical variables will be assessed at entry, 6 months and 1 year (end of study). The EQ5D (quality of life) questionnaires will be collected by the supervising therapist during the follow-up visit and at the same time as the clinical variables.

The main objective is to evaluate the 12-month cost-effectiveness of the management of children diagnosed with ASDs using the e-GOLIAH game used at home, compared to usual management.

Secondary objective includes:

(i) To evaluate the cost-effectiveness ratio of the management of patients with ASDs using e-GOLIAH compared to usual management at 12 months of follow-up.

(ii) To explore the remaining ASD-related annual burden of the cost of disease for the two groups studied.

(iii) To evaluate the consequences of the generalization of the management of children diagnosed with ASD using e-GOLIAH, compared to a usual management, from the point of view of the Health Insurance over a period of 3 years.

(iv) To evaluate the impact of the management of children diagnosed with ASD using the e-GOLIAH game used at home, compared to usual management, on the patient's quality of life and that of their responsible parent and the correlation between the two, on adaptive symptoms, on autistic symptoms, on social interactions, on parental stress, at 6 months and at 12 months.

(v) To assess compliance with OS by children and their caregivers. The following scales will be monitored: the EQ5D-3L for quality of life, the Vineland-II scale, the Child Autism Rating Scale (CARS), the Social Responsiveness Scale (SRS), the Parenting Stress Index. In addition the medico-economic data will be monitored from regular interview and social insurance data.

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: David COHEN, Professor, Child Psychiatrist
  • Phone Number: +33 01 42 16 23 51
  • Email: david.cohen@aphp.fr

Study Contact Backup

Study Locations

  • France
    • Alpes Maritimes
      • Nice, Alpes Maritimes, France, 06200
        • Fondation Lenval - Hôpitaux Pédiatriques de Nice- CHU Lenval
        • Contact:
        • Principal Investigator:
          • Doctor Suzanne THÜMMLER, Child Psychiatrist
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, France, 67091
        • Centre Hospitalier Universitaire de Strasbourg
        • Contact:
          • Professor Carmen SCHRÖDER, Child Psychiatrist
          • Phone Number: +33(0)3.88.11.62.18
          • Email: schroderc@unistra.fr
        • Principal Investigator:
          • Professor Carmen SCHRÖDER, Child Psychiatrist
    • Haut-Garonne
      • Toulouse, Haut-Garonne, France, 31059
        • Centre Hospitalier Universitaire de Toulouse
        • Contact:
        • Principal Investigator:
          • Professor Jean-Philippe RAYNAUD, Child Psychiatrist
    • Hérault
      • Montpellier, Hérault, France, 34295
        • Centre Hospitalier Universitaire de Montpellier
        • Contact:
        • Principal Investigator:
          • Professor Amaria BAGHDADLI, Child Psychiatrist
    • Ile De France
      • Paris, Ile De France, France, 75013
        • Assistance Publique - Hôpitaux de Paris, Site de la Pitié-Salpêtrière
        • Contact:
          • Pr David COHEN, Child Psychiatrist
          • Phone Number: +33(0)1.42.16.23.51
          • Email: david.cohen@aphp.fr
        • Contact:
        • Principal Investigator:
          • David COHEN, Professor, Child Psychiatrist
      • Paris, Ile De France, France, 75014
        • Centre Hospitalier Sainte-Anne / GHU Paris Psychiatrie et Neurosciences
        • Contact:
        • Principal Investigator:
          • Doctor Catherine DOYEN, Child Psychiatrist
      • Paris, Ile De France, France, 75015
        • Assistance Publique - Hôpitaux de Paris, Site de Necker
        • Contact:
          • Professor Pauline CHASTE, Child Psychiatrist
          • Phone Number: +33(0)1.44.49.45.61
          • Email: pauline.chaste@aphp.fr
        • Principal Investigator:
          • Professor Pauline CHASTE, Child Psychiatrist
      • Versailles, Ile De France, France, 78157
        • Centre Hospitalier de Versailles - André Mignot
        • Contact:
        • Principal Investigator:
          • Professor Mario SPERANZA, Child Psychiatrist
    • Indre-et-Loire
      • Tours, Indre-et-Loire, France, 37044
        • Centre Hospitalier Universitaire de Tours
        • Contact:
        • Principal Investigator:
          • Professor Frédérique BONNET-BRILHAULT, Child Psychiatrist
    • Meurthe-et-Moselle
      • Nancy, Meurthe-et-Moselle, France, 54511
        • Centre Hospitalier Universitaire de Nancy
        • Contact:
        • Principal Investigator:
          • Professor Bernard KABUTH, Child Psychiatrist
    • Somme
      • Amiens, Somme, France, 80054
        • Centre Hospitalier d'Amiens
        • Contact:
        • Principal Investigator:
          • Doctor Xavier BENAROUS, Child Psychiatrist
    • Vienne
      • Poitiers, Vienne, France, 86021
        • Centre Hospitalier Universitaire de Paris - Centre Hospitalier d'Henri Laborit
        • Contact:
        • Principal Investigator:
          • Professor Jean XAVIER, Child Psychiatrist

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 6 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria :

  • Child with autism confirmed by a validated instrument (ADI-R or ADOS)
  • Aged 3 to 6 years;
  • Parent(s) agree to get involved in the constraint of using the SG 5 times / week at home for 2 periods of 3 months.
  • Signature of the informed consent form by the 2 holders of parental authority or the only holder of parental authority present
  • Affiliation to a social security scheme (except AME)

Non-inclusion criteria :

  • Children with behavioral problems;
  • Unstabilized comorbid organic pathology;
  • Moderate and severe cognitive deficit (Intellectual Quotient less than 55);
  • Multi or polyhandicap.
  • Medication that may cause visual or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with the study assessments
  • Degenerative diseases or any other disease that could interfere with the evaluations planned during this study (known epilepsy and/or history of seizures, etc.)
  • Photosensitive persons in order to avoid situations that could induce epileptic seizures in them

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
Children receiving the usual care plus intensive use of e-GOLIAH (experimental group)
Device: "e-GOLIAH"
Usual care plus electronic tablet with games application "e-GOLIAH" (Gaming Open Library for Intervention in Autism at Home)
Active Comparator: Control
Children receiving only the usual treatment (control group).
Behavioral: Usual care
Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of Incremental Cost-Utility Ratio (ICUR) at 12 months between the 2 groups
Time Frame: 12 months
ICUR use the 5-level EQ-5D version and the child-friendly EQ-5D version (EQ5D-5L/EQ5D-Y) questionnaires (min score : 0 ; max score : 100 ; higher scores mean a better outcome)
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of Incremental Cost-utility ratio (ICUR) at 6 months between the 2 groups
Time Frame: 6 months
ICUR use the 5-level EQ-5D version and the child-friendly EQ-5D version (EQ5D-5L/EQ5D-Y) questionnaires (min score : 0 ; max score : 100 ; higher scores mean a better outcome)
6 months
Comparison of Incremental cost-effectiveness ratio (ICER) between the 2 groups
Time Frame: 6 and 12 months
ICER use the Vineland II scale (undetermined minimum and maximum)composite score, average score : 100, higher scores mean a better outcome)
6 and 12 months
Comparison of the out of pocket payment for the consumption of treatments linked to the TSA between the 2 groups
Time Frame: 12 months
Amount remaining payable by the patient after deduction of reimbursements received by health insurance
12 months
Budget impact analysis (BIA) of e-GOLIAH in the management of children diagnosed with TSA for health insurance
Time Frame: 3 years
Budget impact analysis (BIA) will be measured by direct resources consumed and quantified using the SNIIRAM/SNDS database
3 years
Comparison of Quality of life between the 2 groups
Time Frame: 6 and 12 months
Measured by the 5-level EQ-5D version and the child-friendly EQ-5D version measured by proxy EQ-5D-5L/EQ-5D-Y(proxy) for the patient and their parent. Scale 0-100 (min score: 0, max score :100, higher scores mean a better outcome)
6 and 12 months
Comparison of Adaptive symptoms between the 2 groups
Time Frame: 6 and 12 months
Use the Vineland-II Scale of socio-adaptive behavior measured by the composite score with an average to 100 of 4 dimensions: socialization, communication, life skills everyday life, and motricity (undetermined minimum and maximum composite score, average score : 100, higher scores mean a better outcome)
6 and 12 months
Comparison of Autistic symptoms between the 2 groups
Time Frame: 6 and 12 months
Use the CARS (Child Autism Rating Ladder) scale, 15 items coded from 1 to 4 (score min: 0, max : 60, higher scores mean a worse outcome)
6 and 12 months
Comparison of Social interactions between the 2 groups
Time Frame: 6 and 12 months
Use the SRS (Social Responsiveness Scale) scale, 65 items coded from 1 to 4 (score min: 0 ; score max : 260, higher scores mean a worse outcome)
6 and 12 months
Comparison of Parental Stress between the 2 groups
Time Frame: 6 and 12 months
Use the Parental Stress Index scale, 36 items coded from 1 to 5 (score min : 0 ; max: 180, higher scores mean a worse outcome)
6 and 12 months
The child's acceptability to the e-GOLIAH game at home
Time Frame: 6 and 12 months
interview with clinical team by phone contact every twice a month for 12 months
6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

University Hospital, Montpellier

Investigators

  • Study Director: David COHEN, Professor, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 15, 2022

Primary Completion (Anticipated)

December 15, 2024

Study Completion (Anticipated)

December 15, 2024

Study Registration Dates

First Submitted

February 28, 2022

First Submitted That Met QC Criteria

February 28, 2022

First Posted (Actual)

March 9, 2022

Study Record Updates

Last Update Posted (Actual)

April 25, 2022

Last Update Submitted That Met QC Criteria

April 15, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • APHP200052
  • 2020-A03389-30 (Other Identifier: IDRCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on "e-GOLIAH"

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe